The FDA has approved Mixject, a new delivery system for triptorelin pamoate (Trelstar), a palliative treatment for advanced prostate cancer. Mixject combines triptorelin depot, 3.75 mg, and long-acting triptorelin, 11.25 mg, with new features that make preparation, administration, and disposal easier, according to Watson Pharmaceuticals, the manufactuer of triptorelin.
The FDA has approved Mixject, a new delivery system for triptorelin pamoate (Trelstar), a palliative treatment for advanced prostate cancer. Mixject combines triptorelin depot, 3.75 mg, and long-acting triptorelin, 11.25 mg, with new features that make preparation, administration, and disposal easier, according to Watson Pharmaceuticals, the manufactuer of triptorelin.
These new features include a smaller, 21-gauge needle for improved patient comfort, reconstitution without the use of a needle, and a shield covering the needle both before and after drug administration. The system is specifically designed to encourage compliance with OSHA regulations within the medical community.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.